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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.07.033Objective: Pulmonary endarterectomy is the operation of choice for thromboembolic
pulmonary hypertension. As the largest referral center for thromboembolic pulmo-
nary hypertension in the world, we are frequently asked whether patients with
extreme pulmonary hypertension (pulmonary artery systolic pressure100 mm Hg)
can safely undergo this operation with therapeutic benefit.
Methods: To determine whether patients with pulmonary artery systolic pressures of
greater than 100 mm Hg have favorable outcomes after pulmonary endarterectomy,
we reviewed the outcomes of 743 patients who underwent this operation between
1999 and 2004. We compared hemodynamic and outcome parameters of 65 patients
(group 1: 26 male and 39 female patients; mean age, 49.5 years) who had preop-
erative pulmonary artery systolic pressures of greater than 100 mm Hg with 678
patients (group 2: 314 male and 364 female patients; mean age, 50.3 years) with
preoperative pulmonary artery systolic pressures of less than 100 mm Hg.
Results: Group 1 patients had a greater overall diminution in pulmonary vascular
resistance (mean decrease: 926.7 511.1 vs 546.4 365.1 dynes · sec · cm5, P
.01) and reduction in pulmonary artery systolic pressure (mean decrease: 50.5 
18.7 vs 27.2  18.6 mm Hg, P  .05), with similar improvement in cardiac output
(mean increase: 1.53  1.47 vs 1.55  1.58 L/min) compared with values seen in
group 2 patients. Although length of hospital stay was similar for the 2 groups,
overall perioperative survival was slightly lower in group 1 patients (89.2% [58/65]
for group 1 vs 96.5% [654/678] for group 2). Patients with extreme pulmonary
hypertension manifest a higher rate of postoperative reperfusion edema, leading to
longer days of intubation compared with group 2 patients.
Conclusions: Pulmonary endarterectomy can be performed safely in patients with
severe thromboembolic pulmonary hypertension. The magnitude of preoperative
pulmonary artery systolic pressure or pulmonary vascular resistance is not a con-
traindication for surgical intervention. Indeed, patients with extreme pulmonary
hypertension might benefit the most from this operation.
Pulmonary hypertension resulting from chronic thromboembolic disease to thelung or recurrent unresolved pulmonary emboli is well known to be a poorprognostic factor for long-term survival and is a cause of significant patient
morbidity.1 Indeed, survival of patients with pulmonary hypertension is inversely
related to the magnitude of pulmonary artery systolic pressure and pulmonary
vascular resistance.2 Pulmonary endarterectomy is the operation of choice for
treatment of chronic thromboembolic disease to the lung. We and others have shown
that pulmonary endarterectomy ameliorates pulmonary hypertension by improving
lung ventilation-perfusion match, arresting right ventricular dysfunction and tricus-
pid regurgitation, limiting retrograde extension of clot obstruction, and preventing
arteriopathic changes in the remaining patent small pulmonary vessels.3,4
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TSA subset of patients with thromboembolic pulmonary
hypertension present for surgical intervention with an ex-
treme form of this disease, with pulmonary artery systolic
pressures in excess of 100 mm Hg and often in excess of
systemic pressures. Although previous case reports and
small series have suggested that this population of patients
has a poor outcome after pulmonary endarterectomy,5-7 no
large study has addressed whether these patients actually
benefit from this operation with acceptable perioperative
mortality and morbidity. This study was designed as a
prospective analysis of patients undergoing isolated pulmo-
nary endarterectomy at our institution over a 5-year period
to examine outcomes in patients with preoperative pressures
exceeding 100 mm Hg, with the goal of determining
whether candidacy for this operation should be limited to
those patients with less extreme forms of disease.
Methods
Patient Selection
We identified and followed all patients who underwent isolated
pulmonary endarterectomy from July 1999 through July 2004 at
our institution. This included 743 patients (340 male and 403
female patients; mean age, 50.2 years; range, 8.9-83.9 years) who
comprise the most recent data set of the University of California,
San Diego Pulmonary Endarterectomy Registry. Patients under-
going concomitant coronary revascularization or valve repair-
replacement at the time of pulmonary endarterectomy were ex-
cluded from this study. The selection criteria for this operation
included the following: (1) pulmonary hypertension with evidence
of thromboembolic disease on pulmonary angiography, (2) pulmo-
nary vascular resistance of greater than 300 dynes · sec · cm5,
and (3) absence of significant noncardiac comorbid disease. For
data analysis, patients were divided into 2 groups: group 1 in-
cluded patients with pulmonary artery systolic pressures exceeding
100 mm Hg (65 patients total; 26 male and 39 female patients;
mean age, 49.5 years), and group 2 included patients with pulmo-
nary artery systolic pressures of less than 100 mm Hg (678 patients
total; 314 male and 364 female patients; mean age, 50.3 years).
According to the usual practice at our institution, all patients
underwent transthoracic echocardiography and preoperative pul-
monary angiography. Measurement of tricuspid regurgitant veloc-
ity was performed in parasternal, apical, and subcostal imaging
positions by using continuous-wave Doppler interrogation, as pre-
viously described.8,9 Confirmatory blind Doppler assessment of
peak TR velocity with a Pedoff continuous-wave probe was also
performed in all patients. Patients older than 45 years underwent
preoperative coronary angiography. Before the operation, Green-
Abbreviations and Acronyms
ICU  intensive care unit
NYHA New York Heart Associationfield vena caval filters were placed in all patients.
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Our surgical method of pulmonary endarterectomy has been pre-
viously described.10 Three surgeons performed all operations on
cardiopulmonary bypass, with a period of circulatory arrest rang-
ing from 3 minutes to 76 minutes (mean, 35.7 minutes) for the
distal-most portion of the endarterectomy procedure for both
lungs. Preoperative hemodynamics were assessed 14 months to 1
day (mean time, 2.3 days; median time, 3 days) before the oper-
ation by means of right-sided heart catheterization (group 1, 62
patients on an elective outpatient basis and 3 patients on an urgent
inpatient basis; group 2, 667 patients on an elective outpatient
basis and 11 patients on an urgent inpatient basis). Postoperative
hemodynamic measurements were made, with each patient weaned
from inotropic and vasodilator support before Swan-Ganz line
(Edwards Lifesciences, Irvine, Calif) removal 1 to 22 days (mean,
2.3 days) after the operation.
Statistical Methods
Results are summarized as means  standard deviation or number
(percentage). 2 Tests were performed to test for statistical signif-
icance for variables measured by frequency, such as the number of
patients in the intensive care unit (ICU) before surgical interven-
tion. Unpaired Student t tests were performed to identify signifi-
cant changes in hemodynamic and other variables within the 2
groups. All Student t tests were 2-sided. Software used for the data
and statistical analyses included S-Plus 6.2 (Insightful Corpora-
tion, Seattle, Wash) and PATS 4.0 (Axis Clinical Software Inc,
Portland, Ore).
Results
All 743 patients in this study underwent bilateral pulmonary
endarterectomy. Characteristics at the time of the operation
for patients with pulmonary artery pressures of greater than
100 mm Hg (group 1) and patients with pulmonary artery
pressures of less than 100 mm Hg (group 2) are detailed in
Table 1. The 2 patient groups were similar with respect to
age and sex. The severity of disease in patients with preop-
erative pulmonary artery pressures exceeding 100 mm Hg
was reflected in presurgical hemodynamic and echocardio-
graphic measurements. As seen in Table 1, patients in group
1 had significant increases in pulmonary artery diastolic
pressures, pulmonary vascular resistance, and degree of
tricuspid regurgitant velocity compared with group 2 pa-
tients before operative intervention. In addition, group 1
patients had a higher percentage of individuals requiring
hospitalization, being treated in the ICU, and requiring
inotropic support before the operation compared with group
2 patients. Patients with pulmonary artery systolic pressures
exceeding 100 mm Hg had relatively higher percentages of
New York Heart Association (NYHA) functional class III
and IV symptoms compared with patients with pulmonary
artery pressures of less than 100 mm Hg. (96.9% NYHA
class III/IV in group 1 compared with 86.5% NYHA Class
III/IV in group 2). Group 1 and group 2 were similar with
respect to the proportion of patients who had a documented
uary 2006
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TShistory of deep venous thrombosis (group 1: 25/65 [38.5%]
patients vs group 2: 295/678 [43.5%] patients) and to the
proportion of patients who had a documented history of
pulmonary embolism (group 1: 44/65 [67.7%] patients vs
group 2: 468/678 [69.0%] patients).
In-hospital survival for all for patients with pulmonary
artery pressures exceeding 100 mm Hg was 89.2% (58/65
patients). Overall survival in this patient group was lower
than survival in patients with pulmonary artery pressures of
less than 100 mm Hg treated during the same time period
(96.5% [654/678] patients). There were no significant dif-
ferences between group 1 and group 2 patients with respect
to cardiopulmonary bypass time, crossclamp time, or circu-
latory arrest time (Figure 1). Total cardiopulmonary bypass
time correlated with body mass and cooling-rewarming
intervals and not with specific preoperative hemodynamic
parameters.
Table 2 presents the mean change between preoperative
and postoperative hemodynamic parameters of pulmonary
artery pressure, pulmonary vascular resistance, and cardiac
output among the 2 patient groups. Postoperative hemody-
namic measurements were made with the patients weaned
from all inotropic and vasodilator support just before Swan-
Ganz line removal. There was a significant difference be-
tween the mean diminution in pulmonary artery systolic
pressure and the mean diminution in pulmonary vascular
resistance measured for patients in groups 1 and 2. Patients
with preoperative pulmonary artery pressures exceeding
TABLE 1. Preoperative patient characteristics
Variable
All patient
(n  743)
Age (y) 50.2 14
Male sex (%) 340 (45.8)
Pulmonary artery pressure (mm Hg)
Systolic 76.2 18
Diastolic 29.3 9.8
Pulmonary vascular resistance (dynes · sec · cm5) 873.6 43
Cardiac output (L/min) 3.9 1.4
Pulmonary capillary wedge pressure (mm Hg) 9.3 4.6
Tricuspid regurgitant jet (M/s) 4.2 0.7
In hospital 24 h preoperatively 166 (22.3)
In ICU preoperatively 12 (1.6)
On intravenous inotropes preoperatively 8 (1.1)
Mechanical ventilation preoperatively 5 (0.7)
NYHA class
I 0 (0)
II 94 (12.7)
III 590 (79.4)
IV 59 (7.9)
Data are shown as means  standard deviation or number (percentage).
York Heart Association. *P value compares groups 1 and 2.100 mm Hg had similar improvement in cardiac output after
The Journal of Thoracisurgical intervention compared with that seen in patients
with preoperative pulmonary artery pressures of less than
100 mm Hg. Improvement in tricuspid regurgitation status,
quantitated by reduction in tricuspid regurgitant jet velocity,
occurred in greater than 97% of individuals in both groups
after surgical intervention, as measured with predischarge
transthoracic echocardiography.
Group 1: PAS >100 mm Hg
(n  65)
Group 2: PAS <100 mm Hg
(n  678) P value*
49.5 15.4 50.3 14.9 .489
26 (40.0) 314 (46.3)
108.1 8.4 73.2 15.7 .002
40.8  8.8 28.2 9.2 .049
1299.0 532.6 832.5 407.2 .002
3.6  1.3 4.0 1.4 .224
10.5 4.7 9.2  4.6 .477
4.8  0.7 4.2 0.7 .444
26 (40.0) 140 (20.6) .001
6 (9.2) 6 (0.9) .001
2 (3.1) 6 (0.9) .102
3 (4.6) 2 (0.3) .001
0 (0) 0 (0)
2 (3.0) 92 (13.5)
53 (81.5) 537 (79.2)
10 (15.4) 49 (7.3)
Pulmonary artery systolic pressure; ICU, intensive care unit; NYHA, New
Figure 1. Comparison of cardiopulmonary bypass, crossclamp,
and circulatory arrest times in patients undergoing pulmonary
endarterectomy. Open bar, Patients with pulmonary artery sys-
tolic pressures of greater than 100 mm Hg; filled bar, patients withs
.9
.1
9.7
PAS,pulmonary artery systolic pressures of less than 100 mm Hg.
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riods of intubation (mean, 7.4 days; median, 3 days) com-
pared with group 2 patients (mean, 3.7 days; median, 1.0
days; Table 3). This led to longer ICU stays for group 1
patients (mean, 9.5 days; median, 6.0 days) compared with
those for group 2 patients (mean, 6.0 days; median, 4.0
days). In general, after pulmonary endarterectomy, the pa-
tients requiring longer periods of intubation did so because
of reperfusion edema after opening of blocked vascular
beds, perioperative pneumonia, or both. With longer periods
of intubation and ICU stays, patients in group 1 had overall
hospital stays that were slightly longer than those of patients
in group 2, although this did not achieve statistical signifi-
cance (group 1 mean length of hospital stay, 18.1 days
[median, 14.0 days]; group 2 mean length of hospital stay,
14.5 days [median, 12.0 days]).
Although patients with pulmonary artery systolic pres-
sures of greater than 100 mm Hg had favorable outcome
with respect to survival, they had a higher incidence of
respiratory-related postoperative complications compared
with patients with pulmonary artery systolic pressures of
less than 100 mm Hg (Table 4). Reperfusion edema neces-
sitating prolonged mechanical ventilation was the most
common perioperative complication for both groups but
occurred with greater frequency in those patients who had
preoperative pulmonary artery systolic pressures of greater
than 100 mm Hg (group 1: 13/65 [20.0%] patients; group 2:
49/678 [7.3%] patients).
Whereas 96% of patients undergoing pulmonary endar-
terectomy for extreme pulmonary hypertension were in
NYHA functional class III or IV before surgical interven-
tion, at the time of discharge, 80.0% of patients were
assessed to be in NYHA functional class I or II. These
results were similar to improvement seen in patients under-
going pulmonary endarterectomy who had lower (100
mm Hg) pulmonary artery systolic pressures. Most (86.5%)
of these patients were in NYHA functional class III or IV
before surgical intervention, with 95.2% of the same cohort
TABLE 2. Comparison of perioperative hemodynamic para
Variable
All patie
(n  74
Mean decrease in PAS (mm Hg) 29.1 1
Mean decrease in PAD (mm Hg) 10.4 1
Mean decrease in PVR (dynes · sec · cm5) 577.6 3
Mean increase in CO (L/min) 1.54 1
Mean decrease in tricuspid regurgitant velocity (M/s) 1.16 0
Data are shown as means  standard deviation. PAS, Pulmonary artery
vascular resistance; CO, cardiac output. *P value compares groups 1 andin NYHA functional class I or II at the time of discharge.
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Pulmonary hypertension caused by chronic thromboembolic
disease is associated with poor long-term survival.11,12 In
the last 15 years, our group has performed more than 1880
pulmonary endarterectomies, with perioperative survival
approaching 4.4%.13 As time has progressed, the technical
hurdles of this operation have been surmounted. However,
despite overall favorable outcomes of pulmonary endarter-
ectomy for thromboembolic disease, there has been little
systematic evaluation of preoperative variables to determine
which of these have the greatest effect on postoperative
outcome. To date, the only factor found useful in predicting
outcome after pulmonary endarterectomy in a large series
has been intraoperative location of thromboembolic dis-
ease.14 Smaller series of less than 35 patients have sug-
gested that pulmonary arterial occlusion pressure waveform
analysis15 and quantitation of plasma brain natriuretic pep-
tide16 might also be useful in predicting surgical outcome.
One of the unresolved problems in the treatment of
chronic thromboembolic disease is the accurate determina-
tion of which subset of patients would be best suited to
surgical intervention. Because of increased awareness of
thromboembolic pulmonary hypertension, several centers
around the world are now reporting results of pulmonary
endarterectomy for small series of patients with this dis-
ease.17-20 Collectively, however, the surgical community
TABLE 3. Postoperative outcome
All patients
(n  743)
Group 1: PAS
>100 mm Hg
(n  65)
Group 2: PAS
<100 mm Hg
(n  678)
Mean/median days
intubated
4.0/1.0 7.4/3.0 3.7/1.0
Mean/median days
in ICU
6.3/4.0 9.5/6.0 6.0/4.0
Mean/median days
in hospital
14.9/12.0 18.1/14.0 14.5/12.0
Mortality (%) 31 (4.2) 7 (10.8) 24 (3.5)*
PAS, Pulmonary artery systolic pressure; ICU, intensive care unit. *P .01
rs
Group 1: PAS >100 mm Hg
(n  65)
Group 2: PAS <100 mm Hg
(n  678) P value*
50.5 18.7 27.2  18.6 .040
19.3 10.3 9.6 9.9 .467
926.7 511.1 546.4  365.1 .002
1.53 1.47 1.55  1.58 .500
1.86 0.84 1.11  0.78 .492
lic pressure; PAD, pulmonary artery diastolic pressure; PVR, pulmonarymete
nts
3)
9.7
0.3
93.8
.57
.80
systofor comparing groups 1 and 2.
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least benefit from this operation and which subset of pa-
tients will be most prone to perioperative complications and
short-term mortality. To this end, we sought to examine
whether patients with extremely high pulmonary artery
pressures experience greater perioperative morbidity-mortality
and whether pulmonary endarterectomy in these patients re-
sults in reduction of pulmonary vascular resistance to normal
or near-normal levels.
We have 3 major conclusions from this study. First,
patients with preoperative pulmonary artery pressures ex-
ceeding 100 mm Hg are, in general, a more ill class of
preoperative patients than individuals with less extreme
forms of this disease. This is reflected in the proportion of
patients with pulmonary artery systolic pressures of greater
than 100 mm Hg in high NHYA functional classes and
greater numbers of these individuals requiring hospitaliza-
tion before surgical intervention. Second, patients with ex-
treme forms of thromboembolic pulmonary hypertension
can satisfactorily undergo this operation with hemodynamic
benefit that is immediate and curative. Third, although sur-
vival rates for patients with markedly increased pulmonary
artery pressures are slightly less than for patients with less
severe pulmonary hypertension, pulmonary endarterectomy
in this patient population is still superior to lung transplan-
tation or heart-lung transplantation. Our institutional sur-
TABLE 4. Perioperative morbidity
Complication
Group 1: PAS
>100 mm Hg
(n  65), no. of
patients (%)*
Group 2: PAS
<100 mm Hg
(n  678), no. of
patients (%)*
Reperfusion edema 13 (20.0) 47 (6.9)
Pneumonia 9 (13.9) 24 (3.5)
Reoperative bleeding 3 (4.6) 18 (2.7)
Atrial fibrillation 2 (3.1) 13 (1.9)
Acute renal failure 2 (3.1) 4 (0.6)
Tracheostomy 2 (3.1) 10 (1.5)
Sternal wound
infection
1 (1.5) 14 (2.1)
Hemothorax 1 (1.5) 2 (0.3)
Pneumothorax 0 9 (1.3)
Chylothorax 0 3 (0.4)
Pleural effusion 0 1 (0.1)
Pericardial effusion 0 7 (1.0)
Femoral-retroperitoneal
hematoma
0 3 (0.4)
Cerebrovascular
accident
0 2 (0.3)
Seizure 0 1 (0.1)
Gastrointestinal bleed 0 3 (0.4)
PAS, Pulmonary artery systolic pressure. *Some patients are counted in
more than 1 category.vival rates after pulmonary endarterectomy in patients with
The Journal of Thoraciextreme pulmonary hypertension (89.2% in the periopera-
tive period in this study and approximately 75% at 5
years21) are superior to survival rates for patients undergo-
ing lung or heart-lung transplantation for this disease, as
reported in the 2004 Annual Report of the US Organ Pro-
curement and Transplantation Network (74% at 3 months
and 39% at 5 years for single- and double-lung transplan-
tation; 80% at 3 months and 48% at 5 years after heart-lung
transplantation for pulmonary hypertension).22
In this study we did find that patients whose preoperative
pulmonary artery pressures exceeded 100 mm Hg were on
average more debilitated before surgical intervention, had
longer postoperative ICU stays, and manifested more major
postoperative complications. Patients with a large diminu-
tion in pulmonary artery pressure after surgical intervention
had, in general, a higher incidence of reperfusion injury to
the lung, requiring longer periods of postoperative ventila-
tory support. For both groups 1 and 2, failure to decrease
pulmonary artery systolic pressure at the time of the oper-
ation was the single factor most predictive of in-hospital
mortality. Reperfusion injury, pneumonia, and acute renal
failure were the complications most associated with pro-
longed periods of hospitalization.
Several lines of evidence suggest that increased pulmo-
nary arterial pressures in chronic thromboembolic pulmo-
nary hypertension are the result of both vascular obstruction
and remodeling of small distal pulmonary arterioles in non-
occluded areas, similar to that seen in primary pulmonary
hypertension. These include (1) an inexact correlation be-
tween the amount of central obstruction and the degree of
pulmonary hypertension,23 (2) pathologic evidence of pul-
monary arteriolar vasculopathy with medial hyperplasia and
hypertrophy in the lungs of patients with thromboembolic
disease,24,25 (3) redistribution of pulmonary blood flow after
pulmonary endarterectomy from nonoccluded to newly end-
arterectomized vascular beds,26 (4) cases of worsening pulmo-
nary hypertension in the absence of recurrent thromboem-
boli,27 and (5) persistent pulmonary hypertension despite
successful endarterectomy in approximately 5% of patients.14
We have found that one of the largest risk factors for
operation remains the degree of operability, as assessed by
pulmonary artery pressure and pulmonary vascular resis-
tance. Patients with high pulmonary artery pressures and
angiographic signs of pulmonary vascular obstruction have
favorable outcomes after this operation. However, high pul-
monary artery pressures with few gross obstructive changes
on angiography signals secondary small-vessel vasculopa-
thy that is not amenable to surgical intervention. Pulmonary
endarterectomy in this subset of patients results in persistent
postoperative pulmonary hypertension that hinders recov-
ery. Arteriolar-capillary vasculopathy represents either un-
diagnosed primary pulmonary hypertensive changes or
small-vessel remodeling that occurs with redistribution of
c and Cardiovascular Surgery ● Volume 131, Number 2 311
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vascular beds to open pulmonary networks. Interestingly,
we have found that small-vessel disease is not homogenous
within the pulmonary vasculature of patients with thrombo-
embolic disease. Arteriolar-capillary medial hyperplasia-
hypertrophy most often occurs in open pulmonary vascular
beds that have not been obstructed by proximal thrombo-
embolic disease.
We appreciate that cardiac remodeling after pulmonary
endarterectomy is not complete in the perioperative period
and that our results reflect only early hemodynamic out-
come and survival. Long-term follow-up in our patient
population is ongoing but challenging because of the fact
that patients in this study were referred for surgical inter-
vention from 10 countries (Great Britain, Australia, New
Zealand, Canada, Belgium, Mexico, Brazil, France, Japan,
and Italy) and more than 30 states. It is our impression that
in patients undergoing pulmonary endarterectomy, long-
term mortality is not influenced by recurrent pulmonary
hypertension unless (1) new untreated pulmonary emboli
occur or (2) the pulmonary endarterectomy was unsuccess-
ful because of a lack of thromboembolic material in the
proximal pulmonary arterial tree and the undiagnosed pres-
ence of microvascular arteriopathy. We believe that no
patient should be denied pulmonary endarterectomy solely
on the basis of the severity of preoperative disease. Indeed,
the subset of patients with extreme forms of pulmonary
hypertension may benefit the most from this operation.
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Discussion
Dr David A. Fullerton (Denver, Colo). I have 3 questions for you.
Your data clearly show that those patients with the highest
degrees of pulmonary hypertension probably benefit the most from
this operation and the operation can be done safely and effectively.
However, as you have alluded to both with your results and in your
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TSmanuscript, this clearly is a higher risk group of patients that had
a greater length of stay, more complications, and higher degrees of
reperfusion injury. Can you share with us some of the insights that
your group has learned and how you need to optimize the care of
these patients? Specifically, I am interested in whether you have
any methods for trying to control the reperfusion injury, acknowl-
edging it will be greater now that you understand that. But is there
anything one can do to attenuate it at the time of surgery?
Dr Thistlethwaite. Thank you very much for your question.
Reperfusion injury is the Achilles heel of pulmonary endarterec-
tomy and it occurs in somewhere between 10% and 20% of all
patients who undergo this operation. Unfortunately, there is not a
clear correlation between worse reperfusion injury and the various
gradations of pulmonary artery pressure. It bears out when you are
looking at large groups in terms of extreme pulmonary hyperten-
sion versus less so, but there is no clear-cut 1:1 correlation. We do
not have any tricks up our sleeve for dealing with this problem.
Our care is mostly supportive. We provide longer periods of
intubation, aggressive diuresis, but nothing more than what would
be standard for other cardiac operations.
Dr Fullerton. Cardiac output was basically the same before
and after the operation in both groups of patients. Acknowledging
that right ventricular afterload is so much higher in your experi-
mental group and that there was a greater diminution in pulmonary
arterial pressure as a result of the operation, I was curious that
cardiac output in your group of interest did not rise to a much
higher degree than in the other group. Did that catch your eye as
well and do you have any insight into that?
Dr Thistlethwaite. It is hard to draw conclusions about im-
provement in cardiac output in this set of patients because there is
a wide range of preoperative pulmonary artery pressures and
pulmonary vascular resistances studied. I would parenthetically
say that most of the patients that are referred to us for this
operation have normal left ventricular function, and those who do
The Journal of Thoracinot (for example, the ones who need concomitant coronary or
mitral valve procedures) were excluded from this study.
Dr Fullerton. Last, I know that your group does not address
the tricuspid valve at the time of surgery. Available data suggest
that it is uncommon that further interventions on the tricuspid
valve are necessary. However, I am still struck by the fact that at
least early on, despite a large reduction in pulmonary arterial
pressure, the pulmonary artery pressures are still elevated. Is there
any particular group that may ultimately require some attention to
the tricuspid valve, or is it fair to say that universally they all get
better and are basically normal?
Dr Thistlethwaite. You highlight a very important point in that
remodeling of the right ventricle is not complete at the time of
surgery but continues afterward. Certainly, tricuspid valve func-
tion would be an interesting thing to look at during longer term
follow-up on our patients. I would say, however, that this is one
system in which a valvular problem is completely reversed by an
operation that does not involve surgery on the valve. I cannot
remember the last time we have had to do any sort of tricuspid
valve procedure in these patients, and the restoration of function,
to a degree that no intervention is needed, is immediate.
Unidentified speaker. Have you some idea of the long-term
results and have you made any attempt to match these groups with
propensity matching or Cox hazard ratio to see whether your
higher risk group is the one that may have the best results if it had
been matched. Have you done this analysis at all and can you give
us something about long-term results?
Dr Thistlethwaite. With regard to long-term results, our pul-
monary endarterectomy registry has been in effect for 8 years and
so long-term results will be forthcoming. This has been particu-
larly difficult because, in this study alone, the patients referred to
us have come from more than 15 countries and more than 40 states.
Long-term follow-up has been somewhat challenging.
We have not attempted to determine statistical analysis match-
ing propensity scores.
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